Patents by Inventor Pratik Devasthale

Pratik Devasthale has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190270741
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Application
    Filed: November 7, 2017
    Publication date: September 5, 2019
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Pratik DEVASTHALE, Fang MOORE, Guohua ZHAO, Susan Nicole PIENIAZEK, Kumaravel SELVAKUMAR, Suresh DHANUSU, Manoranjan PANDA, Lawrence R. MARCIN
  • Publication number: 20190263808
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ay-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Application
    Filed: November 7, 2017
    Publication date: August 29, 2019
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Guohua ZHAO, Pratik DEVASTHALE, Xiang-Yang YE, Kumaravel SELVAKUMAR, Suresh DHANUSU, Palanikumar BALASUBRAMANIAN, Leatte R. GUERNON, Rita CIVIELLO, Xiaojun HAN, Michael Frederick PARKER, Swanee E. JACUTIN-PORTE
  • Publication number: 20190256513
    Abstract: The present invention provides compounds of Formula (I): (Formula (I)), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are inhibitors to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Application
    Filed: November 7, 2017
    Publication date: August 22, 2019
    Inventors: Pratik Devasthale, Wei Wang
  • Patent number: 10369140
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: August 6, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Huji Turdi, Jon J. Hangeland, R. Michael Lawrence, Saleem Ahmad, Wei Meng, Robert Paul Brigance, Pratik Devasthale, Guohua Zhao
  • Patent number: 9974778
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: May 22, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pratik Devasthale, Fang Moore, James Mignone, Wei Wang
  • Publication number: 20180133198
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Application
    Filed: January 11, 2018
    Publication date: May 17, 2018
    Inventors: Huji Turdi, Jon J. Hangeland, R. Michael Lawrence, Saleem Ahmad, Wei Meng, Robert Paul Brigance, Pratik Devasthale, Guohua Zhao
  • Patent number: 9901572
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: February 27, 2018
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Huji Turdi, Jon J. Hangeland, R. Michael Lawrence, Saleem Ahmad, Wei Meng, Robert Paul Brigance, Pratik Devasthale, Guohua Zhao
  • Publication number: 20170216263
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Application
    Filed: April 17, 2017
    Publication date: August 3, 2017
    Inventors: Huji Turdi, Jon J. Hangeland, R. Michael Lawrence, Dong Cheng, Saleem Ahmad, Wei Meng, Robert Paul Brigance, Pratik Devasthale, Guohua Zhao
  • Patent number: 9663466
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: May 30, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Huji Turdi, Jon J. Hangeland, R. Michael Lawrence, Saleem Ahmad, Wei Meng, Robert Paul Brigance, Pratik Devasthale, Guohua Zhao
  • Publication number: 20170114054
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Application
    Filed: June 10, 2015
    Publication date: April 27, 2017
    Inventors: Pratik Devasthale, Fang Moore, James Mignone, Wei Wang
  • Publication number: 20160031816
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Application
    Filed: October 14, 2015
    Publication date: February 4, 2016
    Inventors: Huji Turdi, Jon J. Hangeland, R. Michael Lawrence, Dong Cheng, Saleem Ahmad, Wei Meng, Robert Paul Brigance, Pratik Devasthale, Guohua Zhao
  • Patent number: 9187424
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: November 17, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Huji Turdi, Jon J. Hangeland, R. Michael Lawrence, Dong Cheng, Saleem Ahmad, Wei Meng, Robert Paul Brigance, Pratik Devasthale, Guohua Zhao
  • Publication number: 20150315144
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Application
    Filed: June 16, 2014
    Publication date: November 5, 2015
    Inventors: Huji Turdi, Jon J. Hangeland, R. Michael Lawrence, Dong Cheng, Saleem Ahmad, Wei Meng, Robert Paul Brigance, Pratik Devasthale, Guohua Zhao
  • Patent number: 8791091
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: July 29, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Huji Turdi, Jon J. Hangeland, R. Michael Lawrence, Saleem Ahmad, Wei Meng, Robert Paul Brigance, Pratik Devasthale, Guohua Zhao
  • Patent number: 8754211
    Abstract: The present application provides compounds that are useful as MCHR1 antagonists, especially for the treatment of obesity, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein the variables are defined herein.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: June 17, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pratik Devasthale, William N. Washburn, Kishore V. Renduchintala, Radhakrishnan Sridhar
  • Publication number: 20140031337
    Abstract: The present application provides compounds that are useful as MCHR1 antagonists, especially for the treatment of obesity, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein the variables are defined herein.
    Type: Application
    Filed: September 30, 2013
    Publication date: January 30, 2014
    Applicant: Bristol-Myers Squibb Company
    Inventors: Pratik Devasthale, William N. Washburn, Kishore V. Renduchintala, Radhakrishan Sridhar
  • Patent number: 8580959
    Abstract: The present application provides compounds that are useful as MCHR1 antagonists, especially for the treatment of obesity, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein the variables are defined herein.
    Type: Grant
    Filed: October 8, 2009
    Date of Patent: November 12, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pratik Devasthale, William N. Washburn, Kishore V. Renduchintala, Radhakrishnan Sridhar
  • Patent number: 8415386
    Abstract: The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein all of the variables are defined herein.
    Type: Grant
    Filed: October 8, 2009
    Date of Patent: April 9, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pratik Devasthale, William N. Washburn, Wei Wang, Andres Hernandez, Saleem Ahmad, Guohua Zhao
  • Patent number: 8263659
    Abstract: A method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T3 regulated gene, wherein a compound as described in the general formula I below is administered in a therapeutically effective amount:
    Type: Grant
    Filed: May 21, 2009
    Date of Patent: September 11, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Denis E. Ryono, Jon J. Hangeland, Todd J. Friends, Tamara Dejneka, Pratik Devasthale, Yolanda V. Caringal, Minsheng Zhang, Arthur M. P. Doweyko, Johan Malm, Andrei Sanin
  • Publication number: 20110218185
    Abstract: The present application provides compounds that are useful as MCHR1 antagonists, especially for the treatment of obesity, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein the variables are defined herein.
    Type: Application
    Filed: October 8, 2009
    Publication date: September 8, 2011
    Inventors: Pratik Devasthale, William N. Washburn, Kishore V. Renduchintala, Radhakrishnan Sridhar